PSA Testing and Prostate Cancer Mortality: Evidence Review
This paper examines the controversial question of whether prostate-specific antigen (PSA) testing reduces prostate cancer mortality rates, using an evidence-based nursing practice framework. It identifies PSA screening as a contentious clinical issue, reviews competing research findings, and critically evaluates the evidence. While some studies suggest modest mortality benefits, the weight of evidence indicates that mass PSA testing does not significantly reduce prostate cancer deaths and is associated with overdiagnosis, overtreatment, and psychological harm. The paper concludes by recommending personalized PSA testing — incorporating individual risk factors such as age, family history, race, and genetic variants — as the most suitable evidence-based alternative to population-wide screening campaigns.
- Introduction: Overview of PSA testing controversy and paper scope
- Controversial Issue and Background: Prostate cancer statistics and PSA screening debate
- Literature Review: Key studies on PSA testing and mortality outcomes
- Analysis of Research Evidence: Weighing contradictory PSA mortality evidence
- Most Suitable Alternative to PSA Testing: Personalized PSA testing as evidence-based intervention
- Conclusion: PSA testing verdict and recommended alternative
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Clearly frames a genuine clinical controversy and maintains that framing consistently throughout each section, helping readers understand why the issue matters.
- Presents both sides of the PSA debate before weighing the evidence, demonstrating intellectual fairness while ultimately building a well-supported conclusion.
- Moves purposefully from problem identification to literature review to analysis to a concrete alternative intervention, giving the paper a practical, applied orientation.
Key academic technique demonstrated
The paper demonstrates systematic evidence synthesis within an evidence-based practice (EBP) framework. Rather than simply listing sources, the author evaluates competing studies for methodological strength, flags unverifiable methodology in pro-PSA research, and uses that critique to justify its conclusion. This mirrors the appraisal step used in clinical EBP protocols.
Structure breakdown
The paper follows a four-part EBP structure: (1) identification of the controversial problem, (2) search and presentation of relevant literature, (3) critical evaluation of that evidence, and (4) recommendation of the most suitable intervention. Each section maps directly to one EBP step, making the organizational logic explicit and easy to follow. The conclusion concisely restates the central finding and ties it back to the opening problem statement.
Introduction
Prostate cancer screening is considered one of the crucial steps toward addressing prostate cancer among various patient populations. Healthcare providers regard screening as essential to improving patient health and well-being. In light of its significance to health promotion, several screening tools have been developed and are used in clinical settings, including the digital rectal exam (DRE) and prostate-specific antigen (PSA) testing. PSA testing has received considerable attention in recent years, particularly in relation to its impact on mortality rates.
PSA testing and screening for prostate cancer remain controversial in the modern healthcare setting, given the variance in evidence regarding its effect on mortality rates. This paper examines whether PSA testing reduces mortality rates based on research evidence and evidence-based practice. The analysis is organized around four major steps in evidence-based nursing practice: identification of the controversial problem, search for relevant research studies, evaluation of research evidence, and identification of the most suitable intervention.
Controversial Issue and Background
The controversial issue examined in this paper is PSA testing and its relationship to prostate cancer mortality rates in today's clinical setting. According to Vis (2002), PSA-based testing or screening for prostate cancer is one of the major controversial issues in the modern healthcare sector. PSA testing was established following the increased availability of valid screening tests and the likelihood of success of curative treatment alternatives for prostate cancer. Healthcare providers and authorities in the United States have continued to advocate for PSA testing on the basis of these factors.
Prostate cancer is one of the most common and frequent causes of cancer-related death among men aged 65 years or older. It is reported that prostate cancer is the third leading cause of cancer-related death among American men, following lung cancer and colorectal cancer. Lung cancer accounts for 44.7% of cancer-related deaths, colorectal cancer accounts for 21.2%, and prostate cancer accounts for 20% (Cancer Statistics Center, 2017). The lifetime risk for American men to develop prostate cancer is 16%, whereas the risk of dying from the condition is only 2.9% (American Cancer Society, 2017). Although prostate cancer is a major health problem, most men diagnosed with the condition do not die from it.
Mortality rates associated with prostate cancer have nonetheless received significant attention in the health sector in recent years. Healthcare authorities and professionals consider prostate cancer screening a crucial element in lessening incidence rates, prevalence rates, and mortality rates. Consequently, various tools have been developed to assist in screening, including PSA testing. While PSA testing is regarded as an important tool for prostate cancer screening, it remains controversial — particularly in relation to its impact on mortality rates — and is the central subject of this paper.
Literature Review
Given the controversy relating to PSA testing and mortality rates, the issue has been the subject of numerous studies seeking to enhance understanding and improve clinical practice. Vis (2000) conducted a study to examine whether PSA testing reduces prostate cancer mortality in light of its increased use as a screening tool. The study found that PSA testing does not reduce mortality rates, contrary to widespread belief. The researcher found that the decline in prostate cancer mortality rates, even in countries that utilize PSA testing, is not attributable to those tests but rather to the increased use of curative treatment options. For instance, Canada and several European countries that discourage PSA testing have experienced reductions in mortality rates because of the increased use of curative treatment alternatives (Vis, 2000). These alternatives include diet and lifestyle changes, improvements in environmental conditions, and early application of luteinizing hormone-releasing hormone (LHRH) agonists. Notably, the decline in mortality rates began before the advent of PSA testing.
Howrey et al. (2013) investigated the effect of PSA testing on prostate cancer mortality rates in the United States by comparing PSA testing rates in U.S. counties with prostate biopsy rates, newly-treated prostate cancer cases, and prostate cancer deaths. Based on their findings, PSA testing is linked to a moderate decrease in prostate cancer mortality. The researchers also found, however, that PSA testing contributes to significant increases in the number of men over-diagnosed and over-treated for the condition.
According to a study by Mitka (2012), mass PSA testing does not result in a decrease in the risk of dying from prostate cancer. The research was conducted on an annual, population-wide screening program using serum PSA testing and found that it does not lessen the risk of prostate cancer death. Similarly, Mulhem, Fulbright, and Duncan (2015) contend that PSA testing does not lessen mortality rates. Their study found that PSA testing has low specificity and sensitivity for prostate cancer, and there is a lack of evidence for determining the threshold that necessitates a prostate biopsy. Although prostate cancer screening increases diagnosis of the condition, PSA testing is associated with adverse effects including prostate biopsy complications, overdiagnosis, and overtreatment.
Wilt et al. (2014) state that there is minimal or no benefit of PSA testing among older men or those with limited life expectancy. Even though several prospective trials, simulation models, observational studies, and retrospective analyses have been conducted, PSA testing has been found to be of limited or no benefit with respect to mortality rates. The researchers note broad agreement among relevant stakeholders that harms are linked to downstream clinical actions and that the testing provides minimal to no mortality benefit for prostate cancer patients.
In an earlier study, Slatkoff et al. (2011) found that PSA testing is beneficial in some situations and unhelpful in others. They contend that PSA testing is slightly beneficial to men below the age of 75 years who do not have cancer or cardiovascular risk factors. However, the slight benefit is insufficient to conclude that PSA testing is helpful in prostate cancer diagnosis and treatment. The researchers also argue that PSA testing has significant limitations and potentially harmful effects that largely outweigh its benefits. For example, 75% of positive tests are false positives, which are linked to psychological harm — including increased anxiety and stress — that can persist for up to a year after screening. Factors that contribute to false-positive PSA results include elevated PSA readings, pre-existing conditions such as urinary tract infections, and ejaculation within 24 hours before the test.
On the other hand, some studies indicate that PSA testing is beneficial and can help reduce prostate cancer deaths. Nelson (2014) reviewed the impact of PSA testing on mortality rates and argued that routine PSA testing helps save lives. Based on updated results from the European Randomized Study of Screening for Prostate Cancer (ERSPC), PSA testing has been associated with a significant reduction in prostate cancer mortality rates. However, that study does not recommend routine PSA testing because of its association with overdiagnosis and overtreatment. In a similar vein, Begley (2017) argues that an evaluation of two influential studies on prostate cancer screening indicates that PSA testing lessens death from the condition. One of these influential studies was carried out by the National Cancer Institute — the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial — and focused on determining the impact of screening on cancer-related mortality. The second was conducted by the American College of Physicians and examined the risks and benefits of PSA testing. Begley (2017) postulates that current recommendations against routine PSA screening could be directing men away from a vital, potentially lifesaving process.
Conclusion
One of the most controversial issues in public health policy and healthcare practice is prostate cancer screening. The controversy centers on PSA testing and its relationship to mortality rates. There are ongoing concerns in public health regarding whether PSA testing effectively reduces mortality. Some studies have argued that PSA testing significantly reduces mortality rates, while others have found that it does not. However, a review of existing research evidence demonstrates that PSA testing does not reduce mortality rates and is associated with overdiagnosis and overtreatment. As a result, the most suitable intervention for addressing this problem is a personalized PSA testing approach that incorporates individual risk factors — including age, family history, race, and genetic information — during screening. This approach preserves potential survival benefits while substantially reducing the harms associated with mass population-wide PSA screening campaigns.
References
American Cancer Society, Inc. (2017). Key statistics for prostate cancer. Retrieved October 31, 2017, from https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
Begley, S. (2017, September 5). Do prostate cancer screenings significantly reduce deaths? Scientific American. Retrieved October 31, 2017, from https://www.scientificamerican.com/article/do-prostate-cancer-screenings-significantly-reduce-deaths/
Cancer Statistics Center. (2017). 2017 Estimates. Retrieved November 3, 2017, from https://cancerstatisticscenter.cancer.org/#!/
Carter, H. B., et al. (2011). Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. The Journal of the American Medical Association, 277(18), 1456–1460.
Gulati, R., Gore, J. L., & Etzioni, R. (2013, February 5). Comparative effectiveness of alternative PSA-based prostate cancer screening strategies. Annals of Internal Medicine, 158(3), 145–153.
Helfand, B. T., et al. (2013, May). Personalized PSA testing using genetic variants may reduce unnecessary prostate biopsies. Journal of Urology, 189(5), 1697–1701.
Howrey, B. T., et al. (2013, January). The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. The Journal of Gerontology, Series A: Biological Sciences and Medical Sciences, 68(1), 56–61.
Mitka, M. (2012, January 6). Study: Mass PSA screening does not reduce risk of dying from prostate cancer. Retrieved October 31, 2017, from
Mulhem, E., Fulbright, N., & Duncan, N. (2015, October 15). Prostate cancer screening. American Family Physician, 92(8), 683–688. Retrieved from http://www.aafp.org/afp/2015/1015/p683.html
Nelson, R. (2014, August 6). PSA screening does reduce deaths, but is not recommended. Retrieved October 31, 2017, from https://www.medscape.com/viewarticle/829507
Slatkoff, S., et al. (2011, June). PSA testing: When it's useful, when it's not. The Journal of Family Practice, 60(6), 357–360. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183963/
Vis, A. N. (2002, March 5). Does PSA screening reduce prostate cancer mortality? Canadian Medical Association Journal, 166(5), 600–601. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC99402/
Wilt, T. J., et al. (2014, March 1). Prostate-specific antigen screening in prostate cancer: Perspectives on the evidence. Journal of the National Cancer Institute, 106(3). Retrieved from
Create your account
Always verify citation format against your institution’s current style guide requirements.